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Maria Teresa EspositoAbstract
Blood transfusions are often essential for treatment of severe anaemia and pregnancy complications. The unavailability
of blood is a medical concern, especially in developing countries. New sources of red blood cells (RBC) are under
investigation. Several studies have attempted to produce functional RBC from CD34+ haematopoietic stem cells (HSC)
isolated from peripheral blood and umbilical cord blood, from embryonic stem cells (ESC) and induced pluripotent
stem cells (iPSC). A recent article published in Nature Communications describes a novel model for generating RBC
from a stable erythroid cell line obtained from bone marrow CD34+ haematopoietic stem cells (HSC). The cells
generated by this method are phenotypically and functionally adult RBC, that resemble very well the donor RBC. In
vivo experiments confirmed no difference in the survival of these RBC and donor RBC. The study therefore highlights
that this immortalized line is a promising new source of adult RBC.
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More than 90 million blood transfusions are carried out
every year in the world. The demand for blood is high in
both developed and developing countries. In developed
countries with an improved lifespan, an aging population
with a higher prevalence of diseases might explain the
high demand for blood supply. In developing countries
blood transfusions are essential for treatment of childhood
anaemia and pregnancy complications. While in devel-
oped countries the blood demand might be adequately
met by blood donors, who often represent 1–4% of popu-
lation, in developing countries the blood supply is severely
inadequate. Data from the World Health Organization
(WHO) estimate that developing countries collect less
than 10 donations per 1000 inhabitants. Although blood
transfusions can be life-saving they are not without risks.
Immunological complications, infections, iron overload
and blood mismatch raise concerns and pose a serious
risk to the patients requiring transfusions [1]. Therefore,
the need of blood is equal important as the need of redu-
cing risks for patients.
Stem cells represent an interesting alternative to blood
transfusions as they could ensure adequate supplies of RBC
of a particular blood group and reduce some of the risks
associated with blood transfusions, such as infections.Correspondence: maria.esposito@roehampton.ac.uk
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cells [2]. Several studies have attempted to produce
functional RBC from CD34+ haematopoietic stem and
progenitor cells (HSC) isolated from peripheral blood
[3–5] and umbilical cord blood [3, 5–9], or from human
embryonic stem cells (ESC) [5, 10–14] and induced
pluripotent stem cells (iPSC) [15–17] utilizing different
methods for the differentiation of the stem cells along
the erythroid pathway (Fig. 1a).
The first attempts to generate functional RBC from
CD34+ HSC isolated from peripheral and umbilical cord
blood relied on co-culture with feeder layer to mimic
the bone marrow microenvironment and support cell
expansion and erythroid differentiation [3, 8]. Giarratana
et al. compared the characteristics of RBC obtained from
HSC of diverse origins and expanded with or without
feeder layer [3]. Their results show that in absence of
feeder layer, cell expansion and differentiation is not al-
tered but the enucleation, which corresponds to terminal
differentiation, is severely impaired indicating that the
feeder layer provides fundamental signals for the
complete maturation of RBC [3].
However, the complexity of a co-culture system with
feeder layer impairs the scaling-up of this process for in-
dustrial development.
Years later, the same group and others published feeder-
layer free protocols based on cocktails of cytokines thatle is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Schematic representation of Red Blood Cells (RBC) generation
from distinct sources of stem cells. a) RBC can be derived from
multiple sources of stem cells: iPSc, ESC, cell lines, cord blood,
peripheral blood and bone marrow. b) BEL-A cell line was obtained
by immortalization of bone marrow CD34+ HSC with HPV16-E6/E7
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cleated cells at a high rate [4–7].
Giarratana et al. generated RBC peripheral blood CD34+
HSC obtained by leukapheresis after mobilization with G-
CSF and demonstrated for the first time that these cells
could survive in a human patient as long as donor RBC [4].
The authors used a feeder-layer free protocol based on a
cocktail of cytokines (SCF, IL3 and EPO) that ensured pro-
liferation and erythroid differentiation of CD34+ HSC.
The percentage of enucleated cells and adult haemoglobin
were both very high (over 80%). Theoretically, one unit ofperipheral blood or cord blood can yield multiple units of
RBCs because the erythroid progenitors can be expanded
in vitro. However, the expansion potential of the periph-
eral blood CD34+ progenitors is still a limiting factor,
highlighting the difficulty in adapting this procedure to
the generation of RBCs for routine clinical application.
Although peripheral HSC offer the unique advantage
to allow the production of autologous RBC, some stud-
ies have reported that cord blood CD34+ HSC are a bet-
ter sources of RBC because they have an increased
proliferation potential [3, 5].
RBC generated from cord blood CD34+ HSC show
high percentages of foetal haemoglobin, which has
higher affinity to oxygen than adult haemoglobin.
However, Neildez-Nguyen et al. observed that upon
in vivo injection a switch from foetal to adult
hemoglobin occurred, suggesting that complete mat-
uration of the RBC took place in the bone marrow of
the host mice [6].
An alternative solution to improve the yields is developing
a stable source of cells that can be used for RBC production.
Human ESCs and iPSC give rise to erythroid progeni-
tors that have an expansion potential which in vitro is
greater than the potential of the progenitors derived
from bone marrow, peripheral blood or cord blood.
More importantly, these cells represent a limitless and
immortal source of RBC [18].
In 2007 Lu et al. [11] obtained a precursor of haemato-
poietic and endothelial cells, called haemangioblast, from
human ESC. The authors demonstrated the ability of this
cell to differentiate along multiple haematopoietic lineages
as well as into endothelial cells, in typical CFU assays. How-
ever, the CFU-erythroid cells obtained were very primitive.
The erythrocytes were all nucleated and mainly expressed
foetal globin genes [11]. A year later, in 2008 the same team
published an improved protocol that led to an increase in
yield and maturation of erythroid progenitors [12, 13]. By
growing the cells onto a feeder layer the authors obtained
enucleation in up to 65% of cells and the expression of β-
globin in up to 15% of the cells [12]. The authors attempted
also to generate blood groups A, B, O, and both Rhesus D
positive and Rhesus D negative. However, the authors were
unable to produce the O Rhesus D negative blood type, the
so-called “universal” donor, because of the lack of availabil-
ity of human ESC lines containing the O-negative gene
[12]. Other studies demonstrated the generation of eryth-
roid progenitors from ESC with enforced expression of
transcription factors, such as RUNX1 and HOXB4 but these
studies present limitations in the ability of the cells to sur-
vive in vivo and give rise to adult RBC [2, 10, 14]. Moreover,
the use of transcription factor-overexpression and feeder
layer as well as ethical concerns over the use of cells of em-
bryonic origin represent major hurdles for further transla-
tion to clinical applications.
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the generation of iPSC cells [19] several attempts have
been made to generate RBC from HSC derived by iPSC.
This approach circumvents the ethical concerns of using
embryonic stem cells, however it is limited by similar
technical pitfalls, including transcription factors overex-
pression, use of viruses and feeder layer.
In 2010 Lapillonne et al. described for the first time a 2-
step, feeder-free system to produce RBC from iPSC [15].
They generated iPSC from human foetal and adult fibro-
blasts using the method described by Thomson’s group
[20]. However, by using this method, they obtained enu-
cleation in only up to 10% of RBC generated from iPSC,
and 66% of RBC generated from ESC. Even in this case
the majority of the RBC expressed the fetal γ-globins [15].
Similar results were obtained by Feng et al. [16].
Therefore, although very attractive, ESC and iPSC
might not represent the best choice of stem cells for
blood supply. The differentiation protocols are very long
and RBCs derived from ESCs and iPSC are not fully
adult RBCs and maintain foetal characteristics. RBC de-
rived from ESCs and iPSC express embryonic ε– and
foetal γ-globins with low levels of detectable adult β-glo-
bin. Although ESC are superior to iPSC for the amplifi-
cation and percentages of enucleated RBC, the
enucleation, which represents an important step in the
differentiation of an erythroid progenitor in a mature
RBC, does not reach in iPSC-derived RBC the same per-
centages achieved with RBC obtained from cord and
peripheral blood CD34+ HSC.
An alternative strategy is to generate RBC from im-
mortalized adult erythroid progenitor cell lines. This
strategy could circumvent the limitations of ESCs and
iPSC providing a sustainable and reliable source of adult
RBC (Fig. 1b).
A recent study authored by Trakarnsanga et al. de-
scribes for the first time the generation of such a cell line
[21]. The authors immortalized adult CD34+ HSC by
transduction with an inducible HPV16-E6/E7 construct.
Briefly, after isolating the CD34+ HSC from donor bone
marrow stem cells, the cells were grown in a medium con-
taining cytokines (EPO, Transferrin, SCF, IL-3) for stimu-
lation of erythroid progenitors. The cells were then
infected with lentiviral vectors expressing HPV16-E6/E7
under the control of doxycycline-inducible promoter. The
cells were transferred to an expansion medium containing
EPO, SCF, dexamethasone and doxycycline that induced
the expression of HPV16-E6/E7. The immortalized eryth-
roid cell line was called BEL-A. The cell line was then in-
duced into erythroid differentiation. BEL-A RBC were
morphologically, molecularly and biochemically identical
to those generated by peripheral blood. 94.9% of the de-
rived RBCs produced α and β globin chains as per adult
RBC. BEL-A reticulocytes showed the formation of acontractile ring of F-actin and myosin IIb next to the site
of enucleation, as seen in peripheral blood reticulocytes.
Proteomic analyses confirmed that the BEL-A RBCs no
longer expressed the viral HPV16-E6/E7 proteins. Func-
tional analysis also confirmed proper binding of haemo-
globin with oxygen and carbon dioxide. When injected
into immunodeficient mice (NSG) there was no difference
between the survival of BEL-A RBC and adult donor RBC
[21]. The BEL-A cells showed a mature erythrocyte
morphology 24 h post injection and survived over the
evaluation period (9 days). Further studies will be neces-
sary to evaluate the safety and non-immunogenic nature
of BEL-A RBC before starting a clinical trial.
In summary, this study confirmed that this immor-
talized erythroid cell line could be a reliable source of
adult RBC. In contrast to the protocols developed for
generation of RBC from peripheral and cord blood
CD34+, HSC the method by Trakarnsanga et al. pro-
vides a stable not donor-limited source of RBC. In
contrast to the protocols developed for generation of
RBC from ESC and iPSC, the method by Trakarn-
sanga et al. generated RBC that were functionally
identical to adult donor RBCs.Conclusion
The data reviewed indicate the superiority of such a cell
line over ESC and iPSC as source of RBCs. Bone marrow,
peripheral and cord blood have been considered not eco-
nomically viable sources for RBC production because of
the limited expansion of the progenitor cells and for the
strict dependence of the protocol on cytokines and feeder
layers. Trakarnsanga et al. present an interesting alterna-
tive and permanent source of RBCs able to produce ter-
minally differentiated and functional RBC.
Would it be possible to scale-up this method in order to
meet the requirements of industrial GMP production?
Trakarnsanga et al. attempted to grow the cells in large
spinner flasks and they did not observe issues with prolif-
eration and differentiation however the manufacture of a
proper bioreactor for RBC production and the replace-
ment of the culture media with animal free GMP grade
products was beyond the scope of the study. The use of
viral proteins for the generation of the cell line is unlikely
to raise a risk for clinical use: the expression of these pro-
teins was lost before terminal differentiation and the ma-
ture RBC are enucleated and therefore do not carry any
genetic material.
Notably Trakarnsanga et al. confirmed that the blood
group corresponded to that of the bone marrow donor
from which the cells were created. This means that with
such a methodology it would be possible to generate
RBCs of any blood group. This is particularly important
for patients with rare blood groups.
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